4.7 Review

Receptor-Targeted Glial Brain Tumor Therapies

期刊

出版社

MDPI
DOI: 10.3390/ijms19113326

关键词

Glioblastoma; IL-13RA2; targeted therapies; tumor-associated receptor; peptide vaccines; dendritic cell-based vaccines; CAR T-cell therapy; eph/ephrin receptor system; EGFR/EGF receptor system; immune checkpoint inhibitors; viral/genetic therapies

资金

  1. National Cancer Institute [R01 CA74145, P01 CA207206]
  2. Hearn Fund for Brain Tumor Research
  3. NATIONAL CANCER INSTITUTE [P01CA207206] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Among primary brain tumors, malignant gliomas are notably difficult to manage. The higher-grade tumors represent an unmet need in medicine. There have been extensive efforts to implement receptor-targeted therapeutic approaches directed against gliomas. These approaches include immunotherapies, such as vaccines, adoptive immunotherapy, and passive immunotherapy. Targeted cytotoxic radio energy and pro-drug activation have been designed specifically for brain tumors. The field of targeting through receptors progressed significantly with the discovery of an interleukin 13 receptor alpha 2 (IL-13RA2) as a tumor-associated receptor over-expressed in most patients with glioblastoma (GBM) but not in normal brain. IL-13RA2 has been exploited in novel experimental therapies with very encouraging clinical responses. Other receptors are specifically over-expressed in many patients with GBM, such as EphA2 and EphA3 receptors, among others. These findings are important in view of the heterogeneity of GBM tumors and multiple tumor compartments responsible for tumor progression and resistance to therapies. The combined targeting of multiple receptors in different tumor compartments should be a preferred way to design novel receptor-targeted therapeutic approaches in gliomas.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据